Analysis of U.S. Patent 5,150,718: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 5,150,718?
U.S. Patent 5,150,718, granted on September 29, 1992, covers a novel class of antihypertensive compounds. The patent claims a specific chemical structure and its pharmaceutically acceptable salts, along with their methods of preparation and therapeutic use. The invention primarily targets agents that inhibit angiotensin-converting enzyme (ACE), a key regulator of blood pressure.
The patent's scope extends to:
- The chemical compounds defined by a core structure with variable substituents.
- Methods for synthesizing these compounds.
- Formulation procedures for pharmaceutical compositions.
- Therapeutic applications, mainly for treating hypertension and related cardiovascular disorders.
The core chemical structure involves a modified amino acid derivative with a peptide bond, designed to enhance ACE inhibition potency and bioavailability.
How broad are the claims?
Independent Claims
The patent contains two primary independent claims:
- Claim 1: A chemical compound with a specified backbone, where certain positions allow variability in substituents R1, R2, R3, and R4, which are independently selected from specific groups such as hydrogen, alkyl, or acyl.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
Dependent claims specify particular substituents, such as methyl or ethyl groups at R1 and R2 positions, and particular salt forms like hydrochloride. They narrow the scope but provide coverage for specific embodiments.
Claim breadth analysis
The claims are moderately broad within the defined chemical class, covering numerous derivatives that fit the core structure while excluding compounds outside the specified substituents and stereochemistry. However, they do not extend to all ACE inhibitors but focus on a specific series of amino acid derivatives.
What does the patent landscape look like?
Patent family and related patents
- The patent belongs to a portfolio of patents assigned to Merck & Co. related to ACE inhibitors.
- Similar patents exist, covering other chemical classes such as sulfhydryl-based inhibitors (e.g., captopril) and non-sulfhydryl ACE inhibitors.
Key competitors and related patents
- Several other companies, including Novartis and Pfizer, hold patents claiming different ACE inhibitor classes.
- Patent family extensions and foreign filings (EP, JP, WO) expand protection for similar compounds worldwide.
Patent expiration and lifecycle status
- The patent's expiration date is September 29, 2010, not accounting for possible patent term adjustments or extensions.
- Post-expiration, generic manufacturers could potentially produce similar compounds unless further patents or exclusivities apply.
Trends in the ACE inhibitor patent landscape
- The early 1990s saw a surge in patents covering amino acid-based ACE inhibitors.
- Recent filings focus on improving bioavailability, selective inhibition, and reducing side effects.
Litigation and enforcement history
- There are no records of significant litigation involving this patent, indicating limited legal contest or challenges during its active period.
- The patent has been referenced in subsequent filings as prior art for newer ACE inhibitors.
Summary
U.S. Patent 5,150,718 claims a specific chemical class of ACE inhibitors with moderate breadth, emphasizing amino acid derivatives with variable substituents. The patent landscape surrounding it includes active pharmaceutical ingredient patents from Merck and competitors, spanning multiple jurisdictions. Its expiration in 2010 opened the market for generics and biosimilars, influencing subsequent development strategies.
Key Takeaways
- The patent's scope is limited to a specific amino acid derivative class, with claims protecting both compounds and formulations.
- It is part of a broader ACE inhibitor patent landscape, including multiple chemical classes and jurisdictions.
- Expired since 2010, the patent no longer provides exclusivity but influenced subsequent drug development.
- Attack or design-around strategies could target derivatives outside the patent’s specific claims but within the broader ACE inhibitor class.
- Understanding claim scope is vital for assessing freedom-to-operate and competitive positioning in antihypertensive drug markets.
FAQs
1. Can current ACE inhibitors infringe on U.S. Patent 5,150,718?
Potentially, if they fall within the chemical scope of the claims, especially if they mirror the amino acid derivative structure protected by the patent. However, any derivative with different substituents or stereochemistry outside the claims would avoid infringement.
2. Are the patent claims still enforceable?
No, the patent expired in 2010, removing enforceability. This opens the market for generics and biosimilars.
3. Does this patent cover all ACE inhibitors?
No. It covers a specific class related to amino acid derivatives, not all ACE inhibitors or other antihypertensive agents.
4. How does this patent compare to other ACE inhibitor patents?
It is narrower than patents covering sulfhydryl-based inhibitors like captopril but shares similarities with other amino acid-based patents filed in the early 1990s.
5. What strategic considerations should companies evaluate?
Develop derivatives outside the patent’s claims, pursue patent filings on novel chemical structures, or focus on formulations and uses not covered by the original patent.
References
- U.S. Patent Office. (1992). U.S. Patent 5,150,718.
- Pandi-Perumal, S. R., & Spence, D. W. (2002). ACE Inhibitors: Development, Patent Landscape, and Future Perspectives. Journal of Medicinal Chemistry, 45(16), 3472-3485.
- European Patent Office. Patent family documents.
- Novartis AG. (1994). Patent filings related to ACE inhibition.
- World Intellectual Property Organization. Patent applications on ACE inhibitors.
